Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone (oral) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

NCT02454712
View directory record Official record
Conditions
Healthy
Interventions
PF614, Oxycodone extended-release, Naltrexone Hydrochloride
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Treatment Strategy for Alcohol Use Disorders in Veterans With TBI

NCT01342549
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Valproate, Naltrexone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 3, 2026, 11:24 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

NCT00715117
View directory record Official record
Conditions
Crohn's Disease
Interventions
Naltrexone, Placebo, sugar pill
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Medication and Counseling for Controlled Drinking (Project SMART)

NCT00444418
View directory record Official record
Conditions
Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions
Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

Sweet Preference and Alcohol Craving

NCT01296646
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Abuse
Interventions
Naltrexone, Brenda Therapy Sessions, Placebo
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Results available

ED Initiated Oral Naltrexone for AUD

NCT04817410
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Emergency Department Initiated Oral Naltrexone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

NCT01462227
View directory record Official record
Conditions
Hypoglycemia
Interventions
Naltrexone High Dose, Naltrexone Low Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 3, 2026, 11:24 PM EDT
Withdrawn Early Phase 1 Interventional

Relapse Prevention in Stimulant Use Disorder

NCT04553263
View directory record Official record
Conditions
Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions
Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

NCT01717027
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 3, 2026, 11:24 PM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 3, 2026, 11:24 PM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Alcohol Disorder hOsPital Treatment Trial

NCT02478489
View directory record Official record
Conditions
Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder
Interventions
Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 3, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

NCT00379197
View directory record Official record
Conditions
Breast Cancer
Interventions
naltrexone, PET scan
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

NCT03447782
View directory record Official record
Conditions
New Daily Persistent Headache (NDPH)
Interventions
Naltrexone HCl (Bulk) Powder
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

Impact of Colchicine and Low-dose Naltrexone on COVID-19

NCT04756128
View directory record Official record
Conditions
Covid19
Interventions
Colchicine 0.6 mg, Naltrexone
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 3, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

NCT03132571
View directory record Official record
Conditions
Schizophrenia, Diabetes Mellitus, Type 2, Obesity
Interventions
Naltrexone, Bupropion, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 3, 2026, 11:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 3, 2026, 11:24 PM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 3, 2026, 11:24 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

NCT04678895
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 3, 2026, 11:24 PM EDT
Completed Phase 4 Interventional

Targeted Naltrexone for Problem Drinkers

NCT00369408
View directory record Official record
Conditions
Alcoholism, Alcohol Drinking, Alcohol Dependence
Interventions
Naltrexone, placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 3, 2026, 11:24 PM EDT